CLINICAL OUTCOME AND TOLERANCE OF RADICAL CHEMORADIATION FOR ANAL CANAL CARCINOMA
Main Article Content
Keywords
anal canal carcinoma, chemoradiation
Abstract
Background: Anal canal carcinoma is an uncommon malignancy and concurrent chemoradiation is the standard of care curative treatment in locally advanced anal canal carcinoma. Concurrent chemoradiation have resulted in good outcomes in terms of overall survival, disease free survival. With this study we wanted to assess the clinical outcome of patients with Anal canal carcinoma treated with radical chemoradiation at our centre.
Materials & Methods: This was a retrospective study which included all anal canal carcinoma patients who underwent radical chemoradiation from January 2013 to June 2021 at our centre. Demographic, treatment, toxicity and follow up details were carefully recorded from case records and RT charts.
Results: A total of 18 patients were analysed and the median age of patient population was 59 years. Patients were predominantly males (72%), most common T stage was T3 (72%) and were mostly node positive (67%). Conformal radiotherapy technique was used in all patients. RT dose ranged from 50 Gy to 59.4 Gy, commonest schedule used was 54 Gy in 30 fractions (44%). 17 (94%) patients had acute Grade 3 dermatitis, but Grade 3 or more hematological (2,11%) and gastrointestinal toxicities (1,5%) were less. Out of the 18 patients only one patient could not complete the planned course of RT. Disease free survival at 1 year, 2 years and 3 years were 82.6%, 67.6% and 56.3% respectively. Overall survival at 1 year, 2 years and 3 years were 88.1%, 80.1% and 70.1% respectively.
Conclusion: Our study have shown that Concurrent chemoradiation for Anal canal carcinoma have good outcomes in terms of DFS and OS, with significant incidence of acute Grade 3 dermatitis, with minimal incidence of Grade 3 or more hematological and gastrointestinal toxicity. RT treatment breaks were seen in less proportion of patients and almost all patients completed the planned course of RT.
References
2. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, et al. Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial. JAMA. 2008 Apr 23;299(16):1914–21.
3. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro. https://doi.org/101200/JCO19971552040. 2016 Sep 21;15(5):2040–9.
4. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. https://doi.org/101200/JCO19961492527. 2016 Sep 21;14(9):2527–39.
5. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, et al. Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin. J Clin Oncol. 2012 Dec 12;30(35):4344.
6. Northover JMA, Arnott SJ, Cunningham D, Gallagher J, Gray R, Hardcastle J, et al. Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996 Oct 19;348(9034):1049–54.
7. Neibart SS, Manne SL, Jabbour SK. Quality of Life After Radiotherapy for Rectal and Anal Cancer. Curr Color Cancer Reports 2020 161. 2020 Jan 16;16(1):1–10.
8. Bryant AK, Huynh-Le MP, Simpson DR, Mell LK, Gupta S, Murphy JD. Intensity Modulated Radiation Therapy Versus Conventional Radiation for Anal Cancer in the Veterans Affairs System. Int J Radiat Oncol. 2018 Sep1;102(1):109–15.
9. Call JA, Prendergast BM, Jensen LG. UC San Diego UC San Diego Previously Published Works Title Intensity-modulated Radiation Therapy for Anal Cancer Results From a Multi-Institutional Retrospective Cohort Study Publication Date. Am J Clin Oncol Clin TRIALS. 2014;39(1).
10. Jones CM, Adams R, Downing A, Glynne-Jones R, Harrison M, Hawkins M, et al. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. Int J Radiat Oncol. 2018 Aug 1;101(5):1202–11.
11. Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal. Int J RadiatOncol. 2013 May 1;86(1):27–33.
12. Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017 Apr 1;2(2):110–7.
13. Jethwa KR, Day CN, Sandhyavenu H, Gonuguntla K, Harmsen WS, Breen WG, et al. Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience. Clin TranslRadiat Oncol. 2021 May 1;28:17–23.
14. Hwan Kim K, Suk Chang J, Chang Keum K, Bae Ahn J, Geol Lee C, Sub Koom W. Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience. Radiat Oncol J. 2013;31(1):25–33.
15. Lee WS, Chun HK, Lee WY, Yun SH, Yun H, Cho Yong Beom B, et al. Anal Canal Carcinoma: Experience from a Single Korean Institution. Yonsei Med J. 2007 Oct 31;48(5):827–32.
16. Hammad N, Heilbrun LK, Gupta S, Tageja N, Philip PA, Shields AF, et al. Squamous Cell Cancer of the Anal Canal in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy: A Single Institution Experience. 2011;
17. Possiel J, Ammon HE, Guhlich M, Conradi L-C, Ghadimi M, Wolff HA, et al. Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance. 2021;
18. Tachibana I, Nishimura Y, Inada M, Fukuda K, Ishikawa K, Nishikawa T, et al. Definitive chemoradiotherapy for anal canal cancer: single-center experience. Int J Clin Oncol. 2018 Dec 1;23(6):1121–6.
19. Peixoto RD, Wan DD, Schellenberg D, Lim HJ. A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer. J Gastrointest Oncol. 2016;7(4).
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Akhil P Suresh
Assistant Professor, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India
Greeshma K E
Associate Professor, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India
Vinin N V
Additional Professor, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India
Joneetha Jones
Additional Professor, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India
Ajeena
BSc MRT Intern, Department Of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India
Anitta Francis
Senior Resident, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India
Nabeel Yahiya E K
Assistant Professor, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India
Arun P Narendran
Assistant Professor, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India
Geetha Muttath
Professor, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala, India